Russell Investments Group Ltd. Raises Stock Holdings in Amneal Pharmaceuticals, Inc. $AMRX

Russell Investments Group Ltd. increased its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 81.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 483,804 shares of the company’s stock after purchasing an additional 217,877 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.16% of Amneal Pharmaceuticals worth $4,035,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in Amneal Pharmaceuticals by 6.2% in the first quarter. Vanguard Group Inc. now owns 15,762,727 shares of the company’s stock valued at $132,092,000 after buying an additional 920,758 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Amneal Pharmaceuticals by 5.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,991,702 shares of the company’s stock valued at $39,531,000 after buying an additional 278,653 shares during the last quarter. Nantahala Capital Management LLC raised its stake in Amneal Pharmaceuticals by 37.3% in the fourth quarter. Nantahala Capital Management LLC now owns 3,665,529 shares of the company’s stock valued at $29,031,000 after buying an additional 995,586 shares during the last quarter. Nuveen LLC purchased a new stake in Amneal Pharmaceuticals in the first quarter valued at about $19,581,000. Finally, Invesco Ltd. raised its stake in Amneal Pharmaceuticals by 19.2% in the first quarter. Invesco Ltd. now owns 2,272,713 shares of the company’s stock valued at $19,045,000 after buying an additional 365,467 shares during the last quarter. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

AMRX has been the subject of a number of research analyst reports. The Goldman Sachs Group initiated coverage on Amneal Pharmaceuticals in a research note on Friday, June 6th. They issued a “buy” rating and a $12.00 price target for the company. Wall Street Zen cut Amneal Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 13th. Five equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $11.60.

Insider Buying and Selling

In related news, EVP Jason B. Daly sold 22,000 shares of the firm’s stock in a transaction dated Tuesday, August 12th. The stock was sold at an average price of $9.05, for a total transaction of $199,100.00. Following the sale, the executive vice president directly owned 10,606 shares of the company’s stock, valued at $95,984.30. This trade represents a 67.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Andrew S. Boyer sold 279,244 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $9.38, for a total value of $2,619,308.72. Following the sale, the executive vice president directly owned 152,426 shares in the company, valued at approximately $1,429,755.88. This trade represents a 64.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 456,374 shares of company stock valued at $4,239,042 over the last ninety days. Company insiders own 26.56% of the company’s stock.

Amneal Pharmaceuticals Stock Up 0.6%

Shares of NASDAQ:AMRX opened at $9.59 on Friday. Amneal Pharmaceuticals, Inc. has a 52-week low of $6.68 and a 52-week high of $9.79. The stock has a market cap of $3.01 billion, a price-to-earnings ratio of 959.96 and a beta of 1.11. The business has a 50-day moving average price of $8.38 and a 200-day moving average price of $8.01.

Amneal Pharmaceuticals (NASDAQ:AMRX) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.06. Amneal Pharmaceuticals had a negative return on equity of 189.49% and a net margin of 0.12%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, equities analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.